B. Riley raised the firm’s price target on Kymera Therapeutics to $36 from $31 and keeps a Neutral rating on the shares after the company announced that its partner Sanofi intends to accelerate the development of KT-474 by expanding ongoing Phase II studies. The firm views this development as a mild positive for Kymera shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day
- Kymera Therapeutics Advances with Sanofi in Phase 2 Trials
- Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy
- Kymera Therapeutics Shareholders Approve Key Governance Proposals
- Kymera Therapeutics presents clinical data from Phase 1 trial of KT-333